GlassScriptPhysician profile
Thandavarajan Gopalakrishnan
NPI 1194786137
$3,440.18
in general payments reported to CMS, 2019-2025
31 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $982 · 2021: $676 · 2022: $459 · 2023: $474 · 2024: $201 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $735.13 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.36 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $233.54 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Smith+Nephew, INC. | $220.13 | 2019-2025 | Renasys Touch, Renasys Go V2 Home |
| Astrazeneca Pharmaceuticals LP | $180.25 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.01 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.60 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $154.57 | 2019-2022 | |
| Harmony Biosciences LLC | $153.28 | 2023 | Wakix |
| Otsuka America Pharmaceutical, INC. | $127.47 | 2023-2024 | Nuedexta |
| Musculoskeletal Transplant Foundation INC. | $119.59 | 2020 | |
| Abbvie INC. | $116.27 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $108.62 | 2019-2021 | |
| Pfizer INC. | $95.32 | 2019-2024 | |
| Glaxosmithkline, LLC. | $84.92 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.15 | 2021-2022 | |
| Allergan, INC. | $57.17 | 2020 | |
| Sanofi-Aventis U.S. LLC | $48.63 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $41.09 | 2020 | |
| Philips North America LLC | $39.86 | 2019-2023 | |
| Nevro Corp. | $37.16 | 2019 | |
| Inspire Medical Systems, INC. | $35.82 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $31.16 | 2020 | |
| Aroa Biosurgery Incorporated | $29.55 | 2020 | |
| Arbor Pharmaceuticals, INC. | $27.38 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.08 | 2022 | |
| Kci USA, INC. | $20.03 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.31 | 2023 | Trintellix |
| Tactile Systems Technology INC | $16.76 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.74 | 2025 | Zoryve |
| Ets Wound Care LLC | $9.23 | 2025 | Mirragen Advanced Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thandavarajan Gopalakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.